Recurrent UTIs could be a sign of VUR, Deflux® treatment may help
Deflux is a minimally invasive treatment that has been proven effective in up to 93% of children, with no fUTIs after one injection.
Kalisvaart JF. Intermediate to long-term follow-up indicates low risk of recurrence after double hit endoscopic treatment for primary vesicoureteral reflux. J Ped Urol. 2012;8(4):359-365.
Deflux is a gel made from two tissue-friendly polysaccharides (types of sugars) – hyaluronic acid (HA) and dextranomer (Dx) – and is used as a tissue bulking agent that is injected around the ureteral opening to prevent urine from flowing back up from the bladder through the ureters.
The hyaluronic acid (HA) is naturally broken down (biodegraded) over a short time and replaced by the body’s own material, while the dextranomer remains in place longer. The HA in Deflux is Non-Animal Stabilized Hyaluronic Acid (NASHA®), a patented HA technology that is made from non-animal bacteria and crosslinked specifically for optimal stabilization. NASHA has been used safely for VUR for over two decades and has been used in more than 40 million procedures worldwide, often as a dermal filler.1
A 2019 long-term follow-up study found that 94% of parents were highly satisfied with Deflux treatment.2 Additionally, in a survey of 91 families, 60% of parents preferred treatment with Deflux if they knew prolonged antibiotic therapy had to continue for 3-5 years or when operative treatment was required.3
Deflux endoscopic treatment is indicated for reflux grades 2-4.